<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02430298</url>
  </required_header>
  <id_info>
    <org_study_id>MLT-MX</org_study_id>
    <nct_id>NCT02430298</nct_id>
  </id_info>
  <brief_title>Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients</brief_title>
  <official_title>Topical and Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis and Xerostomia in Head and Neck Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Khon Kaen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ubon Ratchathani Cancer Hospital, Ubon Ratchathani</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Drugs House Ltd., Bangkok</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Khon Kaen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates the effect of melatonin for preventing concurrent radiochemotherapy
      induced oral mucositis and xerostomia and improving quality of life in head and neck cancer
      patients. This is a randomized, double-blind, placebo controlled trial conducted in head and
      neck cancer patients. Mixed-block randomization is used to divide eligible patients into two
      groups: melatonin 40 mg or matched placebo. The patients are required to take the studied
      drugs 20 mg suspensions before radiation and 20 mg capsules at night (after 21.00 pm) on the
      first night of radiation and continue for 7 weeks. Standard treatment is Radiation 2 Gy 5
      fraction/week not more than 7 weeks with Cisplatin chemotherapy base regimen according to
      standard hospital protocol. Study endpoints are level of mucositis (CTCAE scale, WHO scale
      and MTS scores), level of xerostomia (CTCAE scale, VAS), QOL (FACT-H&amp;N), pain (VAS 0-10) and
      adverse event frequency.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of occurrence of mucositis level 3 or more by using the criteria of CTCAE version 4.0, World Health Organization scale and MTSscores</measure>
    <time_frame>Time to event (occurence of mucositis level 3) during 7 weeks of treatment</time_frame>
    <description>Participants will be followed for severity of mucositis during the treatment period of 7 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of occurrence of xerostomia level 2 or more by using the criteria of CTCAE version 4.0 and the Visual Analogue Scale</measure>
    <time_frame>Time to event (occurence of mucositis level 3) during 7 weeks of treatment</time_frame>
    <description>Participants will be followed for severity of xerostomia during the treatment period of 7 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (FACT- H&amp;N Version 4)</measure>
    <time_frame>Change from baseline in Trial Outcome Index scores at 7th week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Matched placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: match placebo Drug: placebo suspension gargle for 2 minutes before radiation 15 minutes and placebo gelatin capsule taken orally after 21:00 hours each night throughout the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melatonin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <description>Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study</description>
    <arm_group_label>Melatonin</arm_group_label>
    <other_name>20 mg/10 ml melatonin suspensions</other_name>
    <other_name>20 mg melatonin gelatin capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched Placebo</intervention_name>
    <description>Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study</description>
    <arm_group_label>Matched placebo</arm_group_label>
    <other_name>20 mg/10 ml placebo suspensions</other_name>
    <other_name>20 mg placebo gelatin capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New diagnostic of head and neck cancer patient who need treatment with radiation
             involved with the oral cavity area.

          -  Never received radiotherapy or chemotherapy

          -  Karnofsky performance status &gt; 70%

          -  Stopped smoking

          -  Able to eat and swallow medications

          -  Written informed consent

        Exclusion Criteria:

          -  Melatonin allergy

          -  Active oral cavity inflammation scar

          -  Pregnancy

          -  Creatinine clearance &lt; 30 ml/min

          -  Active periodontal disease

          -  Steroids or pain killer drugs used for oral cavity pain except NSAIDs for
             thromboembolism prevention

          -  Currently use benzydamine mouthwash
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ubon Ratchathani Cancer Hospital</name>
      <address>
        <city>Ubon Ratchathani</city>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 28, 2014</study_first_submitted>
  <study_first_submitted_qc>April 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <last_update_submitted>February 22, 2016</last_update_submitted>
  <last_update_submitted_qc>February 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Khon Kaen University</investigator_affiliation>
    <investigator_full_name>Nutjaree Pratheepawanit Johns</investigator_full_name>
    <investigator_title>Khon Kaen University</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melatonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

